1Liu YS, Yu CH, Li L, et al. Expression of p53, p16 and cyclooxygenase-2 in esophageal cancer with tissue mieroarray [J].J Digest Diseases, 2007, 8 : 133.
2Weston AP, Banerjee SK, Sharma P, et al. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus : Immunohistochemical marker predictive of progression [J]. Am J Gastroenterol, 2001, 96 : 1355.
3Shimada H, Shiratori T, Takeda A, et al. Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma [J]. World Surgery, 2009, 33 (2):272.
4Miyawaki M, Hijiya N, Tsukamoto Y, et al. Enhanced phosphorylation of the epidermal growth factor receptor at the site of tyrosine 992 in esophageal carcinomas [ J ]. APMIS,2008, 116 (12):1097.
5Gibauh L, Metges J P, Conan-Charlet V, et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer [ J ]. Br J Cancer, 2005, 93 : 107.
6Hoshino M, Fukui H, Ono Y, et al. Nuclear expression of phosphorylated EGFR is associated with poor prognosis of patients with esophageal squamous cell carcinoma [ J ]. Pathobiology, 2007, 74 : 15.
7Gotoh M, Takiuchi H, Ichiro S, et al. Epidermal growth factor receptor is a possible predictor of sensitivity to chemoradiotherapy in the primary lesion of esophageal squamous cell carcinoma [J]. Jpn J Clin Oncol, 2007, 37 (9):652.
8Takayuki Kii, Hiroya Takiuchi, Shinichiro Kawabe, et al. Evaluation of prognostic factors of esophageal squamous cell carcinoma ( stage Ⅱ-Ⅲ) after concurrent chemoradiotherapy using biopsy specimens [ J ]. Jpn J Clin Oncol, 2007, 37 (8):583.
9Yukie Sato-Kuwabara, Jose I Neves, Jose HTG Fregnani, et al. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using fluorescence in situ hybridization (FISH) and immunohistochemistry [J]. BMC Cancer, 2009, 1 (9):6.
10Lagarde SM, Kate FJW, Richel D J, et al. Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction [ J ]. Ann Surg Oncol, 2007, 14 (2):977.
6Loe DW,Deeley RG,Cole SP.Biology of the multidrug resistance associated protein,MRP[J].Eur J Cancer,1996,32A (6):945-957.
7Moran E,Cleary I,Larkin AM,et al.Co-expression of MDR-associated markers,including p-170,MRP and LRP and cytosketal proteins,in three resistant variants of the human ovarian carcinoma cell line,OAW42[J].Eur J Cancer,1997,33(4):652 -660.
8Ikeda K,Oka M,Narasaki F,et al.Lung resistance-related protein gene expression and drug sensitivity in human gastric and lung cancer cells[J].Anticancer Res,1998,18(4C):3077 -3080.
9Cole SP,Bhardwaj G,Gerlach JH,et al.Overexpression of a transporter transporter gene in a multidrug resistant human lung cancer cell line[J].Science,1992,258(5088):1650-1654.
10van der Kolk DM,Vellenga E,Muller M,et al.Multidrug resistance protein MRP1,glutathione,and related enzymes,their importance in acute myloid leukemia[J].Adv Exp Med Biol,1999,457:187-198.
6Lee MH, Lozano G. Regulation of the p53 MDM2 pathway by 14-3-3 sigma and other proteins. Semin Cancer Biol, 2006, 16: 225- 234.
7He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature, 2007, 447:1130- 1134.
8Liu YS, Yu CH, Li L, et al. Expression of p53, p16 and cyclooxygenase-2 in esophageal cancer with tissue microarray. J Dig Dis, 2007, 8:133- 138.
9Chava S, Mohan V, Shetty PJ, et al. Immunohistochemical evaluation of p53, FHIT and IGF2 gene expression in esophageal cancer. Dis Esophagus, 2012, 25: 81- 87.
10Fagundes RB, Mello CR, Tollens P, et al. p53 protein in esophageal mucosa of individuals at high risk of squamous cell carcinoma of the esophagus. Dis Esophagus, 2001, 14: 185- 190.
